Literature DB >> 6141447

Desferrioxamine to improve cardiac function in iron-overloaded patients with thalassemia major.

R E Marcus, S C Davies, H M Bantock, S R Underwood, S Walton, E R Huehns.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1984        PMID： 6141447     DOI： 10.1016/s0140-6736(84)90439-2

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  11 in total

1.  Oral iron chelating drugs: coming but not yet ready for clinical use.

Authors:  C Hershko
Journal:  Br Med J (Clin Res Ed)       Date:  1988-04-16

2.  Effect of iron overload in the isolated ischemic and reperfused rat heart.

Authors:  S Pucheu; C Coudray; N Tresallet; A Favier; J de Leiris
Journal:  Cardiovasc Drugs Ther       Date:  1993-08       Impact factor: 3.727

3.  Radioisotope assessment of heart damage in hypertransfused thalassaemic patients.

Authors:  F Scopinaro; M Banci; A Vania; R Tavolaro; O Schillaci; A Tisei; B Werner; G Digilio; F Ventriglia; V Colloridi
Journal:  Eur J Nucl Med       Date:  1993-07

4.  Haemochromatosis presenting as congestive cardiac failure.

Authors:  J Porter; N Cary; P Schofield
Journal:  Br Heart J       Date:  1995-01

5.  Ventricular diastolic dysfunction in sickle cell anemia is common but not associated with myocardial iron deposition.

Authors:  Jane S Hankins; Mary Beth McCarville; Claudia M Hillenbrand; Ralf B Loeffler; Russell E Ware; Ruitian Song; Matthew P Smeltzer; Vijaya Joshi
Journal:  Pediatr Blood Cancer       Date:  2010-09       Impact factor: 3.167

Review 6.  Iron overload cardiomyopathy: better understanding of an increasing disorder.

Authors:  Pradeep Gujja; Douglas R Rosing; Dorothy J Tripodi; Yukitaka Shizukuda
Journal:  J Am Coll Cardiol       Date:  2010-09-21       Impact factor: 24.094

Review 7.  Benefits and risks of deferiprone in iron overload in Thalassaemia and other conditions: comparison of epidemiological and therapeutic aspects with deferoxamine.

Authors:  George J Kontoghiorghes; Katia Neocleous; Annita Kolnagou
Journal:  Drug Saf       Date:  2003       Impact factor: 5.606

8.  Platelet derived malonyldialdehyde production in patients with thalassaemia major.

Authors:  A P Jewell; R E Marcus
Journal:  J Clin Pathol       Date:  1984-09       Impact factor: 3.411

9.  Atrial and ventricular function in thalassemic patients with supra-ventricular arrhythmias.

Authors:  Ines Monte; Davide Capodanno; Elisa Nicolosi; Salvatore Licciardi; Enrica Talini; Vitantonio Di Bello
Journal:  Heart Int       Date:  2009-06-30

Review 10.  A risk-benefit assessment of iron-chelation therapy.

Authors:  J B Porter
Journal:  Drug Saf       Date:  1997-12       Impact factor: 5.228
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.